MRNA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

633.09M

-34.46%

-2.757

-5.27%

235.15M

+117.73%

-2.340

-7.14%

125.09M

-11.91%

-2.310

+8.45%

Estimates Revision

The market is revising Downward the revenue expectations for Moderna, Inc. (MRNA) for FY2025, with the revenue forecasts being adjusted by -0.67% over the past three months. During the same period, the stock price has changed by 27.84%.

Revenue Estimates for FY2025

Revise Downward

-0.67%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-15.96%

In Past 3 Month

Stock Price

Go Up

+27.84%

In Past 3 Month

20 Analyst Rating

Wall Street analysts forecast MRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 40.13 USD with a low forecast of 17.00 USD and a high forecast of 198.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

13 Hold

4 Sell

Hold

Current: 0.000

Low

17.00

Averages

40.13

High

198.00

Current: 0.000

Low

17.00

Averages

40.13

High

198.00

Wedbush

Outperform

maintain

$26 -> $37

2026-01-07

New

Reason

Wedbush

Price Target

$26 -> $37

2026-01-07

New

maintain

Outperform

Reason

Wedbush raised the firm's price target on Monte Rosa Therapeutics to $37 from $26 and keeps an Outperform rating on the shares after the company announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102 for the treatment of inflammatory conditions. Monte Rosa also expects to initiate a Phase 2 study in atherosclerotic cardiovascular disease patients in 2026, and is currently evaluating additional potential indications including metabolic dysfunction-associated steatohepatitis, gout, and recurrent pericarditis, notes the analyst, who is updating the firm's model to include credit for ASCVD for MRT-8102.

LifeSci Capital

analyst

Outperform

maintain

2026-01-07

New

Reason

LifeSci Capital

analyst

Price Target

2026-01-07

New

maintain

Outperform

Reason

After Monte Rosa announced an update with data from the placebo-controlled Phase 1 trial testing their NEK7-targeted molecular glue degrader, called MRT-8102, LifeSci Capital says that today's initial data will continue to "strongly support investor interest" in the NEK7 MGD program. Given the importance of hsCRP reductions across a range of cardiovascular diseases, it's "not a tremendous surprise to us that the stock is up pre-market," adds the analyst, who has an Outperform rating and a "favorable view on today's dataset."

Jefferies

Buy

maintain

$22 -> $31

2026-01-07

New

Reason

Jefferies

Price Target

$22 -> $31

2026-01-07

New

maintain

Buy

Reason

Jefferies raised the firm's price target on Monte Rosa Therapeutics to $31 from $22 and keeps a Buy rating on the shares after MRT-8102 showed deep reduction of inflammatory biomarker hsCRP in healthy volunteers and subjects with elevated cardiovascular risk in a Phase 1 study. The firm sees the data providing "strong" early proof of concept with broad potential across cardiometabolic diseases, the analyst tells investors.

BofA

Tim Anderson

Underperform

maintain

$21 -> $24

2026-01-06

New

Reason

BofA

Tim Anderson

Price Target

$21 -> $24

2026-01-06

New

maintain

Underperform

Reason

BofA analyst Tim Anderson raised the firm's price target on Moderna to $24 from $21 and keeps an Underperform rating on the shares. Moderna has done "a solid job" of cost cutting from COVID highs, though the firm expects shares will continue to trade around COVID uptake and sentiment in the near-term, with headwinds unlikely to meaningfully abate into the 2026/2027 season, the analyst tells investors.

UBS

Buy

Neutral

downgrade

$40 -> $34

2026-01-06

New

Reason

UBS

Price Target

$40 -> $34

2026-01-06

New

downgrade

Buy

Neutral

Reason

UBS downgraded Moderna to Neutral from Buy with a price target of $34, down from $40, as the analyst assumed coverage of the stock. The firm believes, contrary to guidance, that visibility is low on meaningful revenue growth and break-even or profit by 2028-29, the analyst tells investors. Additionally, the risk/reward for the company's Phase 3 cancer vaccine data in adjuvant melanoma "appears mostly balanced by very binary," the analyst contends.

Wells Fargo

Equal Weight -> Overweight

upgrade

$22

2025-12-16

Reason

Wells Fargo

Price Target

$22

2025-12-16

upgrade

Equal Weight -> Overweight

Reason

Wells Fargo upgraded Monte Rosa Therapeutics to Overweight from Equal Weight with a $22 price target.

Valuation Metrics

The current forward P/E ratio for Moderna Inc (MRNA.O) is -3.67, compared to its 5-year average forward P/E of -1.86. For a more detailed relative valuation and DCF analysis to assess Moderna Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.86

Current PE

-3.67

Overvalued PE

11.47

Undervalued PE

-15.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.03

Current EV/EBITDA

-2.40

Overvalued EV/EBITDA

7.69

Undervalued EV/EBITDA

-11.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.23

Current PS

6.29

Overvalued PS

8.97

Undervalued PS

3.50

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 437.15% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MRNA News & Events

Events Timeline

No data

News

7.0

01-07CNBC

Moderna Shares Rally 21% with 2025 Revenue Target of $1.6B to $2.0B

2.0

01-07Benzinga

Moderna Inc (MRNA) Surges Over 20% in Three Days, Breaking Technical Resistance

3.5

01-07Fool

Amazon Leverages AI to Enhance E-commerce Efficiency, Market Cap Reaches $2.6 Trillion

People Also Watch

Frequently Asked Questions

What is Moderna Inc (MRNA) stock price today?

The current price of MRNA is 34.3 USD — it has increased 1.3 % in the last trading day.

What is Moderna Inc (MRNA)'s business?

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

What is the price predicton of MRNA Stock?

What is Moderna Inc (MRNA)'s revenue for the last quarter?

Moderna Inc revenue for the last quarter amounts to 1.02B USD, decreased -45.44 % YoY.

What is Moderna Inc (MRNA)'s earnings per share (EPS) for the last quarter?

Moderna Inc. EPS for the last quarter amounts to -0.51 USD, decreased -1800.00 % YoY.

What changes have occurred in the market's expectations for Moderna Inc (MRNA)'s fundamentals?

How many employees does Moderna Inc (MRNA). have?

Moderna Inc (MRNA) has 5800 emplpoyees as of January 10 2026.

What is Moderna Inc (MRNA) market cap?

Today MRNA has the market capitalization of 13.40B USD.